Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EIN GUN J SONG

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1548536972
CMS profile
1319821
Location
MILL CREEK, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$41,145.38

195 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–195 of 195 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EIN GUN J SONG

NPI 1548536972 · CMS profile ID 1319821

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

MILL CREEK, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–195 of 195 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548536972?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EIN GUN J SONG, NPI 1548536972, CMS profile ID 1319821. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–195 of 195 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548536972?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). EIN GUN J SONG, NPI 1548536972, CMS profile ID 1319821. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–195 of 195 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548536972?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
EIN GUN J SONG, NPI 1548536972, CMS profile ID 1319821, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–195 of 195 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1548536972?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

195 matching records · $41,145.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 195 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–195 of 195.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.8206/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672174339 CMS
Novartis Pharmaceuticals Corporation $28.4106/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022051 CMS
UCB, Inc. $6.5005/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688329301 CMS
Lilly USA, LLC $21.0705/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657807167 CMS
Novartis Pharmaceuticals Corporation $11.6305/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022037 CMS
AbbVie, Inc. $112.3005/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702845 CMS
Novartis Pharmaceuticals Corporation $23.0005/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022109 CMS
Lilly USA, LLC $99.7005/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657800273 CMS
UCB, Inc. $17.7805/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688330185 CMS
AbbVie, Inc. $102.4405/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702811 CMS
Sun Pharmaceutical Industries Inc. $10.9205/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704576803 CMS
UCB, Inc. $5.7305/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688277939 CMS
Novartis Pharmaceuticals Corporation $6.2304/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022031 CMS
AbbVie, Inc. $20.4704/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702809 CMS
Regeneron Healthcare Solutions, Inc. $17.4504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673480775 CMS
UCB, Inc. $5.4304/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688274657 CMS
UCB, Inc. $24.6004/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688373515 CMS
PFIZER INC. $3.9404/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672696371 CMS
UCB, Inc. $19.2604/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688380117 CMS
AbbVie, Inc. $13.5104/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702807 CMS
UCB, Inc. $3.9004/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688271499 CMS
Novartis Pharmaceuticals Corporation $19.1704/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022047 CMS
Sun Pharmaceutical Industries Inc. $15.6604/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704576795 CMS
UCB, Inc. $4.4404/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688271493 CMS
Sun Pharmaceutical Industries Inc. $7.1604/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704576785 CMS
PFIZER INC. $18.5204/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671970403 CMS
UCB, Inc. $30.0303/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688271489 CMS
Sun Pharmaceutical Industries Inc. $12.0703/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704576779 CMS
Novartis Pharmaceuticals Corporation $25.4003/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022049 CMS
PFIZER INC. $19.6903/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671915871 CMS
Novartis Pharmaceuticals Corporation $19.2203/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022041 CMS
Lilly USA, LLC $5.0503/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657800271 CMS
Novartis Pharmaceuticals Corporation $14.7403/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022039 CMS
AbbVie, Inc. $18.3502/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702803 CMS
Novartis Pharmaceuticals Corporation $28.5702/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022045 CMS
Novartis Pharmaceuticals Corporation $27.4502/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022043 CMS
Sun Pharmaceutical Industries Inc. $7.2602/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704576773 CMS
UCB, Inc. $23.8902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688259665 CMS
PFIZER INC. $16.9602/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672693123 CMS
Lilly USA, LLC $13.9601/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657800269 CMS
AbbVie, Inc. $0.6801/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702801 CMS
AbbVie, Inc. $14.6401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647702805 CMS
Novartis Pharmaceuticals Corporation $17.9101/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022115 CMS
Novartis Pharmaceuticals Corporation $24.9201/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660022053 CMS
Sun Pharmaceutical Industries Inc. $16.7001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704576767 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,145.38 195
PY2020 $135,106.86 176
PY2021 $231,178.37 328
PY2022 $590,765.80 752
PY2023 $1,044,215.72 948
PY2024 $1,204,801.04 1,073
PY2025 $1,289,670.51 1,120

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,146.61 7
PY2025 Principal investigator $370,922.36 110
PY2024 Recipient $990.00 3
PY2024 Principal investigator $371,113.19 82
PY2023 Principal investigator $165,520.88 20
PY2022 Principal investigator $25,141.50 12
PY2021 Principal investigator $22,104.00 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202534809
Principal investigator 1 Janssen Research & Development, LLC $3,744.00 12/25/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345204
Principal investigator 1 Incyte Corporation $1,797.00 12/19/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537122
Principal investigator 1 Incyte Corporation $3,157.20 12/19/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588131
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,182.08 12/18/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434423
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 12/18/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434435
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $162.50 12/11/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434427
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,087.50 12/11/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434431
Principal investigator 1 ABBVIE INC. $5,776.80 12/04/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527244
Principal investigator 1 ABBVIE INC. $3,846.00 12/04/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202527368
Principal investigator 1 Incyte Corporation $7,557.00 12/04/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537120
Principal investigator 1 Incyte Corporation $1,146.10 12/04/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588127
Principal investigator 1 Incyte Corporation $50.00 12/01/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240537124
Principal investigator 1 Janssen Research & Development, LLC $3,291.00 12/01/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345191
Principal investigator 1 Incyte Corporation $306.00 11/25/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537115
Principal investigator 1 Incyte Corporation $4,418.00 11/20/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537107
Recipient PFIZER INC. $3,200.00 11/19/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810977
Recipient PFIZER INC. $3,200.00 11/19/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810983
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,048.39 11/13/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434419
Principal investigator 1 Incyte Corporation $285.00 11/07/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537111
Principal investigator 1 Incyte Corporation $1,474.20 11/07/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588123
Principal investigator 1 ABBVIE INC. $1,198.50 11/04/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520363
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Frontier Dermatology
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997271
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 10/24/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345101
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,015.65 10/23/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434407
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $227.50 10/14/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434411
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $330.00 10/14/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434415
Principal investigator 1 Incyte Corporation $90.00 10/10/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561690
Principal investigator 1 ABBVIE INC. $1,769.20 10/09/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202515153
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 09/29/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345218
Principal investigator 1 Incyte Corporation $1,780.20 09/23/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588117
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,077.14 09/18/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434403
Principal investigator 1 Incyte Corporation $1,488.60 09/12/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537103
Principal investigator 1 Janssen Research & Development, LLC $3,130.00 09/08/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345062
Principal investigator 1 ABBVIE INC. $4,352.10 09/03/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508306
Principal investigator 1 Incyte Corporation $1,674.00 08/21/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588113
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,324.31 08/19/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434398
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,295.76 08/13/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434394
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,273.07 08/12/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434390
Principal investigator 1 ABBVIE INC. $1,288.20 08/06/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202502761
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,500.00 08/06/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434385
Principal investigator 1 ABBVIE INC. $5,486.90 08/05/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501508
Principal investigator 1 Janssen Research & Development, LLC $10,249.00 07/28/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345235
Principal investigator 1 Incyte Corporation $1,585.80 07/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537099
Principal investigator 1 Incyte Corporation $1,656.00 07/10/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588110
Principal investigator 1 Janssen Research & Development, LLC $33,550.00 07/09/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345075
Principal investigator 1 Janssen Research & Development, LLC $420.00 07/07/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345123
Principal investigator 1 Incyte Corporation $3,730.50 07/04/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588106
Principal investigator 1 ABBVIE INC. $11,236.60 07/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495519
Principal investigator 1 ABBVIE INC. $1,125.70 07/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202495531
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $100.00 06/25/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434381
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $130.00 06/24/2025 Non-covered Recipient Entity
Silver Falls Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434377
Principal investigator 1 Janssen Research & Development, LLC $6,370.00 06/23/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345037
Principal investigator 1 Incyte Corporation $60.20 06/20/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537084
Principal investigator 1 Incyte Corporation $1,648.00 06/20/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537095
Principal investigator 1 Incyte Corporation $2,000.00 06/12/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588094
Principal investigator 1 Incyte Corporation $1,200.00 06/12/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588097
Principal investigator 1 Incyte Corporation $10,000.00 06/12/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588102
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 06/12/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175345198
Principal investigator 1 Janssen Research & Development, LLC $420.00 06/09/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345137
Principal investigator 1 ABBVIE INC. $4,773.30 06/03/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202488081
Principal investigator 1 Incyte Corporation $11.45 06/03/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561684
Principal investigator 1 Janssen Research & Development, LLC $2,498.00 05/26/2025 Non-covered Recipient Entity
SILVER FALLS DERMATOLOGY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175345258
Principal investigator 1 Incyte Corporation $1,654.00 05/14/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537071
Principal investigator 1 Incyte Corporation $1,317.80 05/14/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537090
Recipient PFIZER INC. $940.00 05/13/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838846
Recipient ABBVIE INC. $596.61 05/10/2025 Covered Recipient Physician Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202401528
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,662.00 05/08/2025 Non-covered Recipient Entity
Silver Falls Dermatology, Llc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235993685
Principal investigator 1 ABBVIE INC. $1,125.70 05/07/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202483309
Principal investigator 1 ABBVIE INC. $4,521.10 05/07/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202483311
Principal investigator 1 Incyte Corporation $92.00 04/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537060
Principal investigator 1 Incyte Corporation $90.00 04/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537064
Principal investigator 1 Incyte Corporation $1,401.10 04/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537068
Principal investigator 1 Incyte Corporation $90.00 04/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537076
Principal investigator 1 Incyte Corporation $135.00 04/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537080
Principal investigator 1 Incyte Corporation $1,847.00 04/16/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537087
Principal investigator 1 Janssen Research & Development, LLC $183.61 04/04/2025 Non-covered Recipient Entity
Silver Fls Derm Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175264174
Principal investigator 1 ABBVIE INC. $1,277.80 04/03/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202470756
Principal investigator 1 ABBVIE INC. $8,556.10 04/03/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470909
Principal investigator 1 Incyte Corporation $45.80 04/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561679
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537048
Principal investigator 1 Incyte Corporation $10,000.00 04/01/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537052
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240537057
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 03/24/2025 Non-covered Recipient Entity
Silver Fls Derm Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175264182
Principal investigator 1 Incyte Corporation $1,529.90 03/19/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537031
Principal investigator 1 Incyte Corporation $1,648.00 03/19/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537036
Principal investigator 1 ABBVIE INC. $3,979.10 03/07/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202461140
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 02/27/2025 Non-covered Recipient Entity
Silver Fls Derm Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175264167
Recipient PFIZER INC. $940.00 02/27/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838710
Principal investigator 1 Incyte Corporation $1,447.90 02/21/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537027
Principal investigator 1 Incyte Corporation $1,648.00 02/21/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537039
Principal investigator 1 Incyte Corporation $1,648.00 02/21/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537044
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,798.00 02/12/2025 Non-covered Recipient Entity
Frontier Dermatology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997273
Principal investigator 1 ABBVIE INC. $4,235.10 02/06/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202448599
Principal investigator 1 ABBVIE INC. $1,277.80 02/06/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202448604
Principal investigator 1 Janssen Research & Development, LLC $183.61 02/06/2025 Non-covered Recipient Entity
Silver Fls Derm Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175264195
Principal investigator 1 Amgen Inc. $12,448.13 02/05/2025 Non-covered Recipient Entity
FRONTIER DERM PARTNERS
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246641651
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561657
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561665
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561669
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561674
Principal investigator 1 Janssen Research & Development, LLC $183.61 01/31/2025 Non-covered Recipient Entity
Silver Fls Derm Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175264203
Recipient PFIZER INC. $940.00 01/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838616
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $48.12 01/27/2025 Non-covered Recipient Entity
Frontier Dermatology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997269
Principal investigator 1 Janssen Research & Development, LLC $184.96 01/27/2025 Non-covered Recipient Entity
Silver Fls Derm Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175264189
Principal investigator 1 Incyte Corporation $1,847.00 01/24/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537013
Principal investigator 1 Incyte Corporation $2,954.00 01/24/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537016
Principal investigator 1 Incyte Corporation $1,816.70 01/24/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537020
Principal investigator 1 Incyte Corporation $45.00 01/08/2025 Non-covered Recipient Entity
FRONTIER DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240537024
Recipient PFIZER INC. $330.00 01/08/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838718
Principal investigator 1 ABBVIE INC. $4,469.10 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202435023
Principal investigator 1 ABBVIE INC. $1,125.70 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202435027
Principal investigator 1 Incyte Corporation $116.30 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561625
Principal investigator 1 Incyte Corporation $22.90 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561630
Principal investigator 1 Incyte Corporation $34.35 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561636
Principal investigator 1 Incyte Corporation $133.15 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561645
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
NORTH SOUND DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240561653